Natalizumab and PML

被引：0
|
作者：
Richard M Ransohoff
机构：
[1] Neuroinflammation Research Center,Department of Neurosciences
[2] The Cleveland Clinic Foundation,undefined
来源：
Nature Neuroscience | 2005年 / 8卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1275 / 1275
相关论文
共 50 条
  • [1] Natalizumab and PML
    Ransohoff, RM
    NATURE NEUROSCIENCE, 2005, 8 (10) : 1275 - 1275
  • [2] PML with natalizumab
    Reactions Weekly, 2019, 1749 (1) : 8 - 8
  • [3] Stratification of PML risk with natalizumab
    Reactions Weekly, 2012, 1404 (1) : 3 - 3
  • [4] Natalizumab and PML: a risky business?
    Clifford, David B.
    GUT, 2008, 57 (10) : 1347 - 1349
  • [5] A closer look at natalizumab, PML
    Reactions Weekly, 2010, 1303 (1) : 6 - 6
  • [6] PML MRI Patterns in MS Patients Treated with Natalizumab: An Update of Natalizumab PML-MRI Guidelines
    Yousry, Tarek
    Pelletier, Daniel
    Cadavid, Diego
    Gass, Achim
    Richert, Nancy
    Radue, Ernst-Wilhelm
    Filippi, Massimo
    NEUROLOGY, 2012, 78
  • [7] PML: underdiagnosed in MS patients on natalizumab
    Steiner, Israel
    LANCET NEUROLOGY, 2010, 9 (06): : 564 - 564
  • [8] The risk of PML from natalizumab reply
    Ho, Pei-Ran
    Campbell, Nolan
    Chang, Ih
    LANCET NEUROLOGY, 2019, 18 (03): : 230 - 231
  • [9] PML risk and natalizumab: the elephant in the room
    Derfuss, Tobias
    Kappos, Ludwig
    LANCET NEUROLOGY, 2017, 16 (11): : 864 - 865
  • [10] Natalizumab: third case of PML uncovered
    Reactions Weekly, 2005, 1046 (1) : 3 - 3
12345